Latest Research And Development News

PolyNovo Limited reported a robust 28.9% increase in group sales to A$118.6 million for FY25, alongside a 151% surge in net profit after tax to A$13.2 million, driven by strong U.S. growth and key regulatory approvals.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

Carnegie Clean Energy reported a $2.33 million net loss for FY2025 but made significant strides in commercialising its wave energy technologies, supported by new loans and a US subsidiary launch.

Nuix Limited reported an 8% rise in Annualised Contract Value for FY25, driven by a remarkable 132% growth in its Nuix Neo platform. Despite flat revenue, the company achieved a 24.5% increase in Cash EBITDA and outlined a confident outlook for FY26.

Nuix Limited reported a slight revenue increase to $221.5 million for FY25 but swung to a net loss of $9.2 million, weighed down by rising legal fees and restructuring costs. The company’s AI-driven Nuix Neo platform showed strong contract growth, while cash EBITDA improved significantly.

IMDEX Limited posted a modest 3% revenue decline in FY25 but delivered a robust 15% rise in EBITDA and a striking 70% jump in net profit, driven by strong growth in digital and SaaS platforms. The company’s strategic acquisitions and sustained R&D investment position it well for future expansion.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

BCI Minerals has transitioned to full-scale operations at its Mardie Salt Project, marking a pivotal moment with strong construction progress, secured financing, and binding offtake agreements. The company remains on track for first salt shipment by late 2026.

Cogstate Limited has reported a landmark FY25 with revenue up 22% and net profit before tax nearly doubling, driven by a surge in clinical trials contracts and strategic innovation. The company also declared its maiden fully franked dividend and outlined ambitious growth plans including AI product launches and an expanding Medidata partnership.

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.

PWR Holdings Limited posted a 6.7% revenue decline and a 60.6% drop in net profit for FY2025, impacted by contract completions and factory relocation. Despite short-term setbacks, the company is investing heavily in new facilities, aerospace growth, and sustainability initiatives.

Objective Corporation Limited reported a robust FY2025 with 15% growth in annualised recurring revenue, driven by strong SaaS adoption and strategic AI integration across its GovTech portfolio.